Predictors of decision to pursue fertility preservation prior to gonadotoxic therapy in male pediatric, adolescent, and young adults patients

Abbey Riazzi, Megan Sax, Elizabeth Spitznagel, Marion Schulte, Brycen Ferrara, Olivia Frias, Brian VanderBrink, Paul Noh, Bob DeFoor, Jr., Eugene Minevich, Pramod Reddy, Karen Burns, Julie Rios, Andrew Strine



Pediatric cancer

- Increasing incidence with almost 16,000 cases diagnosed between 0-19 years of age in US in 2018.
- Improving survival due to advent of more effective multimodal therapies
 - >80% now surviving into adulthood
- Recent interest in late effects on fertility with evergrowing number of survivors
 - Less gonadotoxic therapies
 - Fertility preservation (FP)



Siegel et al. CA Cancer J Clin 2018

Fertility preservation

- Sperm cryopreservation (SCP)
 - Most established option for FP
 - Should be offered to all adolescent and young adult patients prior to gonadotoxic therapy.
- Testicular tissue cryopreservation (TTC)
 - Experimental
 - Greatest potential for FP before puberty



Objective

 To identify the factors that influence the decision to pursue FP prior to gonadotoxic therapy in male pediatric, adolescent, and young adult patients.




Methods

- Retrospective cohort study for male patients who were evaluated for FP between September 2013 and October 2018
- Risk stratification based on cyclophosphamide equivalent dosing
 - Low: <20% of permanent azoospermia
 - Intermediate: 20-80%
 - High: >80%

- Exclusions
 - Consultation for FP declined by family
 - Prior consultation for FP
 - Second opinion
 - Observation only
 - Surgery only
 - Exposure to chemotherapy within 3 months of SCP
 - Phase I clinical trial
 - Palliative therapy







	FP (n=102)	No FP (n=133)	<i>p</i> -value
Age in years, median (IQR)	15.5 (12.6-17.6)	10.8 (2.8-16.3)	<0.001
Pubertal development, n (%) Pre-pubertal Peri- or post-pubertal	29 (28.4) 73 (71.6)	80 (60.2) 53 (39.8)	<0.001
Race, n (%) White Middle Eastern Black Other Refused or unknown	69 (67.6) 17 (16.7) 8 (7.8) 6 (5.9) 2 (2.0)	87 (65.4) 20 (15.1) 14 (10.5) 10 (7.5) 2 (1.5)	0.93
Primary language, n (%) English Other	85 (83.3) 17 (16.7)	111 (83.5) 22 (16.5)	1.00
Religion, n (%) Christian Muslim Other Refused or unknown	47 (46.1) 18 (17.6) 1 (1.0) 36 (35.3)	61 (45.9) 22 (16.5) 1 (0.8) 49 (36.8)	0.99



	FP (n=102)	No FP (n=133)	<i>p</i> - value
Insurance, n (%) Private Public International None or self pay	66 (64.7) 18 (17.6) 16 (15.7) 2 (2.0)	61 (45.9) 46 (34.6) 20 (15.0) 6 (4.5)	0.01
Prior treatment, n (%)	14 (13.7)	25 (18.8)	0.38
Risk assessment, n (%) Low Intermediate High None	8 (7.8) 22 (21.6) 61 (59.8) 11 (10.8)	20 (15.1) 12 (9.0) 93 (69.9) 8 (6.0)	0.01
Care team, n (%) Bone marrow transplant Neuro-oncology Leukemia/Lymphoma Solid cancer Other	35 (34.3) 7 (6.9) 24 (23.5) 33 (32.4) 3 (2.9)	62 (46.6) 14 (10.5) 28 (21.1) 29 (21.8) 0 (0.0)	0.04



	Adjusted OR*	<i>p</i> -value*
Pubertal development		
Pre-pubertal	1.00 (reference)	
Peri- or post-pubertal	12.34	<0.001
Insurance		
Private	5.40	0.08
Public	1.21	0.85
International	6.82	0.06
None or self pay	1.00 (reference)	
Risk assessment		
Low	1.00 (reference)	
Intermediate	5.93	0.004
High	4.53	0.01
None	3.80	0.07
Care team		
Bone marrow transplant	1.00 (reference)	
Neuro-oncology	0.37	0.12
Leukemia/Lymphoma	0.45	0.17
Solid cancer	0.54	0.24
Other	0.23	0.98

* Multivariate logistic regression analysis



Conclusions

 A peri- or post-pubertal status as well as an intermediate- and high-risk stratification were associated with pursing FP.

• Further research is needed to better characterize the barriers to FP in this population.



Thank You